Metformin hydrochloride sustained release biopolymeric system composed by PLLA‐CMC microparticles

Metformin hydrochloride (MetHCl) is a drug extensively used to treat diabetes mellitus Type 2. However, its high hydrophilicity drastically reduces its metabolic absorption. Consequently, high drug concentrations should be taken by patients to achieve the desired therapeutical efficiency, causing se...

Full description

Saved in:
Bibliographic Details
Published inJournal of applied polymer science Vol. 138; no. 33
Main Authors Silva, Thiago Schroeder, Silva, Denise Abatti Kasper, Nogueira, André Lourenço
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 05.09.2021
Wiley Subscription Services, Inc
Subjects
biopolymers and renewable polymers
Carboxymethyl cellulose
cellulose and other wood products
Diabetes mellitus
Differential scanning calorimetry
drug delivery systems
Emission analysis
Emulsifiers
Encapsulation
Field emission microscopy
Lactic acid
Materials science
Metformin
Microparticles
Polymers
Side effects
Spectrophotometry
Sustained release
Thermogravimetric analysis
Online AccessGet full text

Cover

More Information
Summary:Metformin hydrochloride (MetHCl) is a drug extensively used to treat diabetes mellitus Type 2. However, its high hydrophilicity drastically reduces its metabolic absorption. Consequently, high drug concentrations should be taken by patients to achieve the desired therapeutical efficiency, causing several side effects. The present study proposes the development of a MetHCl sustained release biopolymeric system composed of poly(l‐lactic acid) (PLLA) and carboxymethyl cellulose (CMC) as a strategy to minimize the problems aforementioned. The PLLA‐CMC microparticles were produced by the double emulsion‐solvent evaporation technique using two distinct emulsifiers in the first emulsion (Span 80 and Tween 80). The microparticles were characterized by ultraviolet–visible spectrophotometry, scanning electron microscopy with field emission gun, thermogravimetric analyses, and differential scanning calorimetry (DSC). Additionally, in vitro drug release assays were performed. The results demonstrated that the emulsion stability and encapsulation efficiency increased in a dependent fashion way with the CMC concentration. DSC findings showed that the choice of the emulsifier of the first emulsion influences the polymer particle's crystallinity and, consequently, the releasing behavior of the drug. The in vitro studies revealed that the encapsulation of MetHCl in PLLA‐CMC microparticles is a promising sustained release system compatible with a zero‐order kinetic mechanism.
ISSN:0021-8995
1097-4628
DOI:10.1002/app.50806